Friedreich's Ataxia News and Research

RSS
Friedreich's ataxia is an inherited disease that causes progressive damage to the nervous system resulting in symptoms ranging from gait disturbance and speech problems to heart disease. A well-known celebrity afflicted with Friedreich's ataxia is former major leaguer and noted historian Clinton Stewart.
Viropharma announces financial results for second quarter of 2013

Viropharma announces financial results for second quarter of 2013

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

Friedreich's Ataxia costs between £11,000 and £19,000 per person per year

Friedreich's Ataxia costs between £11,000 and £19,000 per person per year

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Study discovers pathways that govern instability of GAA/TTC repeats

Study discovers pathways that govern instability of GAA/TTC repeats

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

ViroPharma initiates maribavir Phase 2 program for CMV infections

ViroPharma initiates maribavir Phase 2 program for CMV infections

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma to acquire Meritage

ViroPharma to acquire Meritage

UPC develops active knee-ankle orthosis to assist gait in people with incomplete SCI

UPC develops active knee-ankle orthosis to assist gait in people with incomplete SCI

FARA announces 2011 Ataxian Athlete Initiative grant recipients

FARA announces 2011 Ataxian Athlete Initiative grant recipients

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

MDA announces $13.7M in grants to 40 new muscular dystrophy research initiatives

MDA announces $13.7M in grants to 40 new muscular dystrophy research initiatives

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen first quarter total revenue increases 9% to $7,654,000

Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia

Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011